NCT07700823Not yet recruiting
Two-Point Versus Single-Point Serratus Anterior Plane Block for Post-Thoracoscopic Surgery Analgesia
Comparison of Ultrasound-Guided Two-Point Combined vs Single-Point Serratus Anterior Plane Block for Postoperative Analgesia in Thoracoscopic Surgery: A Prospective Observational Cohort Study
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
Postoperative pain remains a common clinical challenge in patients undergoing video-assisted thoracoscopic surgery (VATS), impairing early recovery and increasing opioid consumption. The serratus anterior plane block (SAPB) is a widely used regional analgesic technique for thoracic surgery, but conventional single-point injection may have limited spread of local anesthetics, resulting in suboptimal analgesia in some patients. Preliminary anatomical evidence suggests that two-point combined SAPB may achieve wider dermatomal coverage and better analgesic efficacy. This is a single-center, prospective observational cohort study conducted at Shanghai Pulmonary Hospital, China. A total of 88 adult patients scheduled for elective unilateral VATS will be consecutively enrolled and naturally assigned to either the two-point combined SAPB group (injection at the 3rd and 5th rib levels, total 30 ml local anesthetic) or the single-point SAPB group (injection at the 5th rib level, 30 ml local anesthetic) according to routine clinical practice. The primary outcome is the verbal rating scale (VRS) pain score on coughing at 24 hours postoperatively. Secondary outcomes include resting and dynamic pain scores at multiple time points, cumulative opioid consumption at 24 and 48 hours, incidence of postoperative nausea and vomiting, block-related complications, length of hospital stay, and Quality of Recovery-15 (QoR-15) scores. This study aims to provide clinical evidence for optimizing perioperative analgesic strategies for thoracoscopic surgery.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 88 (estimated)
- First submitted
- 8 Jul 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Shiyou Wei
- Diseases
- Lung cancer
- NCT number
- NCT07700823
What you commit to
- Study type: Observational
- Planned participants: 88
- From 1 Aug 2026 to the primary completion date, 1 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Preexisting sensory abnormality in the chest wall surgical area
Other illness
- Local infection or skin lesion at the block puncture site
- Known hypersensitivity or allergy to amide local anesthetics
- Chronic opioid use for \> 3 months, history of chronic pain syndrome, or history of opioid abuse
- Cognitive impairment or inability to cooperate with postoperative pain assessment
Lab values
- Severe coagulopathy (international normalized ratio \> 1.5 or platelet count \< 80 × 10⁹/L)
Other
- Refusal to provide written informed consent
Who the study is looking for
- Aged 18 to 85 years at enrollment, regardless of sex
- American Society of Anesthesiologists (ASA) physical status grade I to III
- Scheduled for elective unilateral video-assisted thoracoscopic surgery
- Planned to receive ultrasound-guided SAPB for routine perioperative analgesia
- Able to understand study procedures and provide written informed consent
Age in the registry: 18 years to 85 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.